Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Reads0
Chats0
TLDR
Several glutamate receptor-modulating agents have been tested in proof-of-concept studies for mood disorders as discussed by the authors, and most have shown relatively modest effects compared with (R,S)-ketamine and esketamine, though some have shown more favorable characteristics.Abstract:
The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders. In particular, rapid reductions in depressive symptoms have been observed in response to subanesthetic doses of the glutamatergic modulator racemic (R,S)-ketamine in individuals with mood disorders. These results have prompted investigation into other glutamatergic modulators for depression, both as monotherapy and adjunctively. Several glutamate receptor-modulating agents have been tested in proof-of-concept studies for mood disorders. This manuscript gives a brief overview of the glutamate system and its relevance to rapid antidepressant response and discusses the existing clinical evidence for glutamate receptor-modulating agents, including (1) broad glutamatergic modulators ((R,S)-ketamine, esketamine, (R)-ketamine, (2R,6R)-hydroxynorketamine [HNK], dextromethorphan, Nuedexta [a combination of dextromethorphan and quinidine], deudextromethorphan [AVP-786], axsome [AXS-05], dextromethadone [REL-1017], nitrous oxide, AZD6765, CLE100, AGN-241751); (2) glycine site modulators (d-cycloserine [DCS], NRX-101, rapastinel [GLYX-13], apimostinel [NRX-1074], sarcosine, 4-chlorokynurenine [4-Cl-KYN/AV-101]); (3) subunit (NR2B)-specific N-methyl-d-aspartate (NMDA) receptor antagonists (eliprodil [EVT-101], traxoprodil [CP-101,606], rislenemdaz [MK-0657/CERC-301]); (4) metabotropic glutamate receptor (mGluR) modulators (basimglurant, AZD2066, RG1578, TS-161); and (5) mammalian target of rapamycin complex 1 (mTORC1) activators (NV-5138). Many of these agents are still in the preliminary stages of development. Furthermore, to date, most have demonstrated relatively modest effects compared with (R,S)-ketamine and esketamine, though some have shown more favorable characteristics. Of these novel agents, the most promising, and the ones for which the most evidence exists, appear to be those targeting ionotropic glutamate receptors.read more
Citations
More filters
Journal ArticleDOI
mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development
Shigeyuki Chaki,Mai Watanabe +1 more
Journal ArticleDOI
Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders
Pratik Chakraborty,Abhijit Dey,Abilash Valsala Gopalakrishnan,Kumari Swati,Shreesh Ojha,Anand Prakash,Dhruv Kumar,Rashmi K. Ambasta,Niraj K. Jha,Saurabh Kumar Jha,Saikat Dewanjee +10 more
TL;DR: In this paper , the scope of developing glutamatergic systems as prospective pharmacotherapeutic targets to treat cognitive disorders is discussed, and some drugs that regulate glutamate receptor activities have shown therapeutic promise in improving cognitive functions in preclinical and clinical studies.
Book ChapterDOI
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders.
TL;DR: The role of glutamate system in the etiology and pathophysiology of psychiatric disorders has gained considerable attention in the past two decades, including dysregulation of the metabotropic glutamatergic receptor subtype 5 (mGlu5) as discussed by the authors .
Journal ArticleDOI
Differential genetic associations and expression of PAPST1/SLC35B2 in bipolar disorder and schizophrenia
Akihito Uezato,Daisuke Jitoku,Dai Shimazu,Naoki Yamamoto,Akeo Kurumaji,Yoshimi Iwayama,Tomoko Toyota,Takeo Yoshikawa,Vahram Haroutunian,Eduard-Mihai Bentea,J. Meller,Courtney R. Sullivan,James H. Meador-Woodruff,Robert E. McCullumsmith,Toru Nishikawa +14 more
TL;DR: Findings indicate that SLC35B2 might be differentially involved in the pathophysiology of BD and SCZ by influencing the sulfation process and/or glutamate system in the central nervous system.
Journal ArticleDOI
Discovery of a Series of Substituted 1H-((1,2,3-Triazol-4-yl)methoxy)pyrimidines as Brain Penetrants and Potent GluN2B-Selective Negative Allosteric Modulators.
Christine F. Gelin,Brice Stenne,Heather Coate,Afton S. Hiscox,Aki Soyode-Johnson,Jessica L. Wall,Brian Lord,Jeffrey Schoellerman,Kevin J. Coe,Kai Wang,Jesús Alcázar,Christa C. Chrovian,Curt A. Dvorak,Nicholas I. Carruthers,Tatiana Koudriakova,Bartosz Balana,Michael A. Letavic +16 more
TL;DR: In this article , a series of substituted 1H-((1,2,3-triazol-4-yl)methoxy)pyrimidines are described as potent GluN2B negative allosteric modulators.
References
More filters
Journal ArticleDOI
Antidepressant effects of ketamine in depressed patients
Robert M. Berman,Angela Cappiello,Amit Anand,Amit Anand,Dan A. Oren,Dan A. Oren,George R. Heninger,Dennis S. Charney,Dennis S. Charney,John H. Krystal,John H. Krystal +10 more
TL;DR: A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression.
Journal ArticleDOI
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate,Jaskaran Singh,Paul J. Carlson,Nancy E. Brutsche,Rezvan Ameli,David A. Luckenbaugh,Dennis S. Charney,Husseini K. Manji +7 more
TL;DR: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.
Journal ArticleDOI
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Nanxin Li,Boyoung Lee,Rong-Jian Liu,Mounira Banasr,Jason M. Dwyer,Masaaki Iwata,Xiaoyuan Li,George K. Aghajanian,Ronald S. Duman +8 more
TL;DR: The results demonstrate that the effects of ketamine are opposite to the synaptic deficits that result from exposure to stress and could contribute to the fast antidepressant actions of ketamines.
Journal ArticleDOI
Steroid Hormone Metabolites are Barbiturate-Like Modulators of the GABA Receptor
Maria Dorota Majewska,Neil L. Harrison,Rochelle D. Schwartz,Jeffery L. Barker,Steven M. Paul +4 more
TL;DR: Two metabolites of the steroid hormones progesterone and deoxycorticosterone are potent barbiturate-like ligands of the gamma-aminobutyric acid (GABA) receptor-chloride ion channel complex and potentiated the inhibitory actions of GABA in cultured rat hippocampal and spinal cord neurons, which may explain the ability of certain steroid hormones to rapidly alter neuronal excitability.
Journal ArticleDOI
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
TL;DR: The findings suggest that ketamine may disrupt dopaminergic neurotransmission in the PFC as well as cognitive functions associated with this region, in part, by increasing the release of glutamate, thereby stimulating postsynaptic non-NMDA glutamate receptors.